睿知中国医院研究地图
候选清单

即将招募淋巴瘤II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T-Cell Lymphoma

ClinicalTrials.gov 上登记的一项淋巴瘤开放试验,由上海交通大学医学院附属瑞金医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方(推断)上海交通大学医学院附属瑞金医院Ruijin Hospital上海医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07535762,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 6

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(6 项)收起清单
  1. 65 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Patients with histologically confirmed peripheral T-cell lymphoma (PTCL) who have not previously received treatment

    入选标准第 5 条

  3. Previous immunotherapy or chemotherapy for PTCL, excluding those who used corticosteroids (≤8 days) prior to enrollment

    排除标准第 3 条

  4. ECOG performance status score ≤ 2

    入选标准第 3 条

  5. Absolute neutrophil count (ANC) ≥ 1,500/μL

    入选标准第 11 条

    Platelet count ≥ 100,000/μL

    入选标准第 12 条

    Total bilirubin ≤ 1.5 times the upper limit of normal (ULN) for the institution (except for patients with Gilbert's syndrome)

    入选标准第 13 条

    Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN; if liver involvement is known, then ≤ 5.0 × ULN

    入选标准第 14 条

    Serum creatinine ≤ 1.5 × ULN, or creatinine clearance > 50 mL/min calculated by the Cockcroft-Gault formula

    入选标准第 15 条

  6. Known or detected positive for human immunodeficiency virus (HIV), human T-cell leukemia virus (HTLV-1), hepatitis B, or hepatitis C.

    排除标准第 15 条

    Patients diagnosed with malignancy within the past two years. However, the following are excluded: non-melanoma skin cancer, melanoma in situ, localized prostate cancer (current PSA <0.1 ng/mL), treated thyroid cancer; or cervical carcinoma in situ or breast ductal/lobular carcinoma in situ within the past two years, provided there is currently no evidence of active disease.

    排除标准第 16 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);影像与可测量病灶;怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07535762,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Understand and voluntarily sign the informed consent form
  2. Age ≥ 65 years at enrollment
  3. ECOG performance status score ≤ 2
  4. Able to comply with the research visit plan and other protocol requirements
  5. Patients with histologically confirmed peripheral T-cell lymphoma (PTCL) who have not previously received treatment
  6. Peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS)
  7. Nodal T-follicular helper cell lymphoma (TFH)
  8. Anaplastic large cell lymphoma, ALK-negative (ALCL)
  9. Life expectancy ≥ 3 months
  10. Hematological, renal, and hepatic function all meet the requirements:
  11. Absolute neutrophil count (ANC) ≥ 1,500/μL
  12. Platelet count ≥ 100,000/μL
  13. Total bilirubin ≤ 1.5 times the upper limit of normal (ULN) for the institution (except for patients with Gilbert's syndrome)
  14. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN; if liver involvement is known, then ≤ 5.0 × ULN
  15. Serum creatinine ≤ 1.5 × ULN, or creatinine clearance > 50 mL/min calculated by the Cockcroft-Gault formula

排除标准:Exclusion Criteria:

  1. Mental illness, disability, or social circumstances that may affect participant safety, ability to provide informed consent, or poor adherence
  2. Other types of lymphoma
  3. Previous immunotherapy or chemotherapy for PTCL, excluding those who used corticosteroids (≤8 days) prior to enrollment
  4. Previous radiotherapy for PTCL, excluding those confined to a single lymph node region
  5. Pathological immunohistochemistry showing CD30 positivity and/or ALK positivity
  6. Patients planning to receive autologous or allogeneic transplantation as first-line consolidation therapy
  7. Confirmed central nervous system/meningeal involvement
  8. Significant uncontrolled comorbidities or infections, specifically:
  9. Uncontrolled infection requiring intravenous antibiotics
  10. Clinically significant heart disease (NYHA Class III or IV), unstable angina
  11. History of angioplasty, stent implantation, or myocardial infarction within the past 6 months
  12. Uncontrolled hypertension (systolic blood pressure >160 mmHg) despite using two antihypertensive medications. (or diastolic blood pressure >100 mmHg, measured twice consecutively, one week apart)
  13. Clinically significant cardiac arrhythmias
  14. Uncontrolled diabetes
  15. Known or detected positive for human immunodeficiency virus (HIV), human T-cell leukemia virus (HTLV-1), hepatitis B, or hepatitis C.
  16. Patients diagnosed with malignancy within the past two years. However, the following are excluded: non-melanoma skin cancer, melanoma in situ, localized prostate cancer (current PSA <0.1 ng/mL), treated thyroid cancer; or cervical carcinoma in situ or breast ductal/lobular carcinoma in situ within the past two years, provided there is currently no evidence of active disease.

引自 ClinicalTrials.gov, NCT07535762, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07535762,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07535762